STING/type I interferon pathway is required for antigen-containing PLGA nanoparticle- and apoptotic cell–induced CD4+ T cell tolerance
Science Advances · 2026
DOI: 10.1126/sciadv.adv8860 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2026. Verfasst von Joseph R Podojil und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology-Immunology, Northwestern University, Chicago, IL, USA. Hauptthemen laut MEDLINE: CD4-Positive T-Lymphocytes, cGAS-STING Signaling Pathway, Interferon Type I, Antigens. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Institutes of Health, Juvenile Diabetes Research Foundation, Cour Pharmaceuticals.
Abstract (Originalsprache)
Autoreactive CD4 + T cell infiltration, tissue destruction, and spread epitope–specific CD4 + T cell activation underly CD4 + T cell–mediated autoimmune disease pathogenesis. Here, we identify previously unknown pathways required for antigen (Ag)–specific tolerogenic immune-modifying particle/Cour nanoparticle (TIMP/CNP)–induced tolerance. The data show that myeloid cells phagocytose CNPs, undergo apoptosis, and release oxidized DNA [8-hydroxy-2′-deoxyguanosine (8-OHG)]. Subsequently, Ag-specific CNP treatment increases the number of PD-L1 + cDC2 dendritic cells and the number of FoxP3 + , CTLA-4 + , PD-1 + , and IL-10 + regulatory CD4 + T cells via a stimulator of interferon genes (STING)/interferon-α/β receptor (IFNAR)–dependent pathway. In addition, these same pathways were found to be required for both Ag-coupled apoptotic leukocyte–induced and Ag-coupled red blood cell treatment–induced CD4 + T cell tolerance. Together, these results show that Ag-specific tolerance induced by the presence of apoptotic cells, and by CNP-induced apoptosis, requires the STING/IFNAR pathway, thereby illustrating a previously unknown function of this pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Microbiology-Immunology, Northwestern University, Chicago, IL, USA.
- Center for Human Immunobiology, Northwestern University, Chicago, IL, USA.
- Cour Pharmaceutical Development Company, Skokie, IL, USA.
- Urology Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
- Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA.
ORCID-Profile: Joseph R Podojil, Andrew C Cogswell, Tobias Neef, Gabriel Arellano, Sandeep Kakade, Derrick P McCarthy, Chris T Harp, Joshua J Meeks, Lonnie D Shea, Stephen D Miller
Förderung
- National Institutes of Health
- Juvenile Diabetes Research Foundation
- Cour Pharmaceuticals
- Johnnie Walkers MS Foundation
- Amy and David Fulton Foundation
- Crammer Family Foundation
- Thomas and Deige McLaughlin Foundation
- Rottering Family Foundation
Zitieren
APA
Podojil, J. R., Cogswell, A. C., Neef, T., Chiang, M. Y., Beddow, S. A., Arellano, G., Kakade, S., McCarthy, D. P., Elhofy, A., Harp, C. T., Khan, M., Meeks, J. J., Xu, D., Shea, L. D., & Miller, S. D. (2026). STING/type I interferon pathway is required for antigen-containing PLGA nanoparticle- and apoptotic cell–induced CD4+ T cell tolerance. Science Advances. https://doi.org/10.1126/sciadv.adv8860
Vancouver
Podojil JR, Cogswell AC, Neef T, Chiang MY, Beddow SA, Arellano G, et al. STING/type I interferon pathway is required for antigen-containing PLGA nanoparticle- and apoptotic cell–induced CD4+ T cell tolerance. Science Advances. 2026. doi:10.1126/sciadv.adv8860
BibTeX
@article{Podojil2026,
author = {Podojil, Joseph R and Cogswell, Andrew C and Neef, Tobias and Chiang, Ming-Yi and Beddow, Sara A and Arellano, Gabriel and Kakade, Sandeep and McCarthy, Derrick P and Elhofy, Adam and Harp, Chris T and Khan, Mairah and Meeks, Joshua J and Xu, Dan and Shea, Lonnie D and Miller, Stephen D},
title = {STING/type I interferon pathway is required for antigen-containing PLGA nanoparticle- and apoptotic cell–induced CD4+ T cell tolerance},
journal = {Science Advances},
year = {2026},
doi = {10.1126/sciadv.adv8860}
}
EUVIMED